Navigation Links
Gene therapy promising for growing tooth-supporting bone

A University of Michigan research team has found that introducing a growth factor protein into a mouth wound using gene therapy helped generate bone around dental implants, according to a new paper in the February issue of the journal Molecular Therapy.

In a patient with a sizeable mouth wound, replacing a tooth takes more than simply implanting a new one---the patient also needs the bone structure to anchor the new tooth in place. Such reconstructive surgery today involves either taking a bone graft from the patient's chin or jaw, which leaves a second wound needing to heal, or using donated bone from a tissue bank, which yields unpredictable results.

William Giannobile, professor of periodontics, prevention and geriatrics, led a team at the U-M School of Dentistry that delivered the gene encoding for bone morphogenetic protein-7 (BMP-7) to large bone defects in rats in an attempt to turn on the body's own bone growth mechanisms. The study showed that animals that got the BMP-7 treatment produced nearly 50 percent more supporting bone around dental implants than those receiving the conventional treatment.

"This study represents a proof-of-concept investigation. We are encouraged about the promise of this treatment," said Giannobile, also an associate professor of biomedical engineering and director of the Michigan Center for Oral Health Research.

More work will need to be done before the approach can be tested in humans, Giannobile added. He said he optimistically would like to see initial trials begin in humans in four to seven years.

BMP-7 is part of a family of proteins that regulates cartilage and bone formation. Recent studies have shown that BMPs are present in tooth development and periodontal repair.

This study mixed BMP-7 genes with an inactivated virus in a gel-like carrier and injected it into wounds. Giannobile said using a virus, with the harmful effects turned off, harnesses the virus' ability to enter in to cells and use their genetic machinery.

Once inside the cell, the viruses help BMP-7 genes get where they need to be in the host's cells to boost bone production. Gene expression producing BMP-7 proteins peaked after a week. Giannobile said that was ideal because the team did not want to make any permanent genetic changes. The gene acted quickly to get bone growth started, then disappeared within about 28 days.

Giannobile said a next step in this process could include looking for non-viral approaches to delivering gene therapy to the defect site. Alternatively, scientists could conduct the gene therapy outside the body using a tissue biopsy and then transplant the genetically-modified cells back into the patient, but this would require two surgical procedures instead of one.

The Molecular Therapy paper is titled "BMP Gene Delivery for Alveolar Bone Engineering at Dental Implant Defects," and the work was supported by the National Institutes of Health and National Institute of Dental and Craniofacial Research.

Giannobile is part of a cross-campus program called Tissue Engineering at Michigan, funded in part by the National Institute for Dental and Craniofacial Research. TEAM aims to provide an interdisciplinary, research-intensive environment for those pursuing careers in the oral sciences, with a focus in the area of restoration of oral-craniofacial tissues.

Co-authors on the paper include Courtney A. Dunn, adjunct clinical lecturer in orthodontics; Qiming Jin, research associate in periodontics, prevention and geriatrics; Mario Taba Jr., research fellow in periodontics, prevention and geriatrics; Renny T. Franceschi, associate dean for research and professor of periodontics, prevention and geriatrics, all at the U-M School of Dentistry. Francesci also is a professor of biological chemistry. R. Bruce Rutherford, a former U-M Dentistry professor who now serves as chief scientific officer of private tissue engineering firm Ivo clar Vivadent-Dentigenix, was a co-author, as well.


'"/>

Source:University of Michigan


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, ... office dedicated to the North American healthcare market. , Aerocom Healthcare, LLC will ... The company will provide new pneumatic tube systems or expand existing systems ...
Breaking Biology Technology: